Reifenstein Dialysis Center is a medicare approved dialysis facility center in Juneau, Alaska and it has 9 dialysis stations. It is located in Juneau county at 9109 Mendenhall Mall Rd Suite #6, Juneau, AK, 99801. You can reach out to the office of Reifenstein Dialysis Center at (907) 790-3002. This dialysis clinic is managed and/or owned by Renal Care Group Inc.. Reifenstein Dialysis Center has the following ownership type - Profit. It was first certified by medicare in March, 2004. The medicare id for this facility is 022504 and it accepts patients under medicare ESRD program.
| Name | Reifenstein Dialysis Center |
|---|---|
| Location | 9109 Mendenhall Mall Rd Suite #6, Juneau, Alaska |
| No. of Dialysis Stations | 9 |
| Medicare ID | 022504 |
| Managed By | Renal Care Group Inc. |
| Ownership Type | Profit |
| Late Shifts | No |
| 9109 Mendenhall Mall Rd Suite #6, Juneau, Alaska, 99801 | |
| (907) 790-3002 | |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
| NPI Number | 1215049010 |
| Doing Business As | Dialysis Services Of Southeast Alaska, Llc |
| Address | 9109 Mendenhall Mall Rd Juneau, Alaska, 99801 |
| Phone Number | (907) 790-3002 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
| Dialysis patients with Hemoglobin data | 13 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 8 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 22 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 153 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
| Adult patients getting regular peritoneal dialysis at the center | 7 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 54 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Reifenstein Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 26 |
| Hypercalcemia patient months | 214 |
| Patients with Serumphosphor | 28 |
| Patients with Serumphosphor less than 3.5 mg/dL | 4 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 15 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 21 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 37 |
| Patients with Serumphosphor greater than 7 mg/dL | 23 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 29 |
| Patient months included in arterial venous fistula and catheter summaries | 145 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 66 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 3 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 23 |
| Hospitalization Rate in facility | 109.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 307 |
| Hospitalization Rate: Lower Confidence Limit | 42.1 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
The rate of readmission show you whether patients who were being treated regularly at Reifenstein Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 18.4 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 54.5 |
| Readmission Rate: Lower Confidence Limit | 2.7 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Reifenstein Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.73 (As Expected) |
| SIR: Upper Confidence Limit | 5.72 |
| SIR: Lower Confidence Limit | .29 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Reifenstein Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 22 |
| Transfusion Rate in facility | 20.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 159 |
| Transfusion Rate: Lower Confidence Limit | 3.5 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
The rate of mortality show you whether patients who were being treated regularly at Reifenstein Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 104 |
| Mortality Rate in facility | 27.1 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 43.3 |
| Mortality Rate: Lower Confidence Limit | 15.8 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago
Reifenstein Dialysis Center Location: 9109 Mendenhall Mall Rd Suite #6, Juneau, Alaska, 99801 Phone: (907) 790-3002 |
News Archive
A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago